Immunoprecipitation
293T cells were transiently transfected with pcDNA3.1 expressing HA tagged FBXW7 and FBXW7-ΔF respectively using Fugene (Roche). The cells were harvested 24 hours after the transfection and lysed in lysis buffer (50 mM Hepes pH 7.5, 250 mM NaCl, 0.5% NP40 or 0.25% dodecyl beta D maltoside in 1x PBS with protease inhibitors) incubated on ice for 60 min and centrifuged at 13,000g for 15 min. The supernatant was collected and protein concentration was estimated with the Pierce BCA assay reagent. 500µg of lysates were precleared with protein G-sepharose beads (GE Healthcare) and incubated with 2 µg of antibody overnight. Addition of protein G sepharose beads with incubation for 3-4 hour followed. After the incubation, the beads were washed three times with the lysis buffer described above and the precipitates were subjected to immuno blotting as below. For the immunoprecipitation with anti HA antibody, Profound HA Tag IP/Co-IP kit (Pierce) was used according to the instruction manual.
TaqMan assay
We designed TaqMan primers and probes using the Primer Express Oligo Design Software v1.0 (Applied Biosystems). Probes are FAM probes designed specifically for TaqMan (Applied Biosystems). All primer sets were used to perform amplifications in triplicate on the ABI 7700 instrument (Applied Biosystems, Foster City, CA, USA). Reactions (50 μl) were performed in 1 TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 1.6 nM primer, 0.4 nM probe, 12.5 ng DNA. Cycling parameters were as follows: 95°C for 12 min 1 cycle, (95°C for 20 s, 60°C for 20 s, 72°C for 60 s) 40 cycles. Copy number was determined from the PCR cycle number (CT) at which DNAs reach a threshold amount of fluorescence above background. To normalize for differences in the amount of total input DNA, amplification at a reference locus is performed once per plate in triplicate for each individual DNA. The CT values for each set of triplicates are averaged. The Ct of the pooled reference is subtracted from the CT for each locus to obtain the CT ( CT=CT (locus)-CT (reference)). Ct values are determined for locus in tumor samples and a set of six normal genomic DNAs. The average of the six CT values ( CT(normal)) measured from the normal DNAs was calculated once for each locus in the study and used in the subsequent calculations for all experiments performed on a single ABI 7700.
CT= Ct (tumor)-Average CT (normal). If CT>0.5, it means gain; If CT<-0.5, it means loss.
Viable cell count analysis
Cell number was measured using the CellTiter-Glo Luminescent assay (Promega) according to the manufacturer's instructions, and luminescence was recorded with a luminometer (BioTek FLx800, BioTek Instruments, Inc.). The cells are seeded in 96 well plates and exposed to mTOR inhibitor rapamycin (100 nM to 2 μM) for 72 hours. The number of cells used per experiment is determined empirically. Each cell line and drug concentration will be set up in 6 replicate wells and repeated at least 3 times.
shRNA constructs and retrovirus production
A shRNA with high FBXW7 knockdown efficiency was cloned into pSuper retrovirus cassettes (OligoEngine). The shRNA sequences for FBXW7 are GTGTGGAATGCAGAGACTGGAGA (17). The breast cancer cell lines (MDA-MB453, LY2 and MCF7) were infected with high-titre retroviral stocks produced by the transient transfection of 293T ecotropic Phoenix cells. After infection with the pSuper retrovirus allowing the expression of shRNA molecules, cells were selected with 1-2µg /ml of puromycin in the culture medium. The control of the experiment was pSuper vector without shRNA.
Plasmids and mutagenesis
The fragment of human mTOR was amplified from human cDNA by PCR using the primers (CCCAAGCTTGAACCTCAGGGCAAGATGCT) and (GCTCTAGATTAGATCCAAAGCCCCTAAAAGC). The fragment was digested with HindIII and XbaI, and cloned into the HindIII-XbaI site of the p3XFLAG-CMV-10 expression vector. The two mutants (delT631 and T631G) were generated by in vitro sitedirected mutagenesis using QuickChange II Site-Directed Mutagenesis Kit (Stratagene, La Jolla, USA). The primers for delT631 mutagenesis are TCCCGCCTGCTCCCCTCCATCCAC and GTGGATGGAGGGGAGCAGGCGGGA, for T631G, CTCCCGCCTGCTCGGACCCTCCATCCAC and GTGGATGGAGGGTCCGAGCAGGCGGGAG. All constructs were verified by sequencing.
Nude mouse injections 5x10 6 SUM149PT cells and 5x10 6 MDA-MB453 cells was injected subcutaneously in 10 nude mice in opposing flanks. 8 days after inoculation, 10 nude mice was divided into two groups, one was treated with rapamycin daily (4mg per kg body weight) for 11 days, the other with placebo. Tumor sizes were measured with a caliper every two days. The tumor volume is calculated using the formula: Volume= S×S×L/2, where s is the short length of the tumor in mm and L is the long length of the tumor in mm.
Statistical analysis
The Chi-square test was used to check whether loss of FBXW7 and deletion or mutation of PTEN is mutually exclusive in human breast cancer cell lines and primary tumors. The logistic regression analysis has been used in combination data set. All analyses were carried out using SPSS. Figure S1 . Identification of Fbxw7 novel targets by genome-wide search using CPD sequences. Comparison of minimal consensus CPD sequences found in mTOR with those of the known human target proteins cyclin E (CCNE) and c-MYC. Figure S2 . CPD sequences of mTor are evolutionarily conserved in different species ranging from humans to zebra fish. Figure S3 . The levels of mTOR and p-mTOR, as well as the downstream mTOR target S6-kinase (P-S6), are upregulated by depletion FBXW7 in human colon cancer cell lines HCT116 and DLD1, whereas the levels of AKT and p-AKT (lower panels) were not appreciably affected. Figure S6 . The regulation of mTOR by FBXW7 is through the proteasome-dependent degradation pathway. 293T and SUM149PT cells were transfected with a vector containing CMV promoter-driven HA-ubiquitin. Immunoprecipitation of mTOR followed by Western blot analysis of the HA-ubiquitin showed that in 293T cells which have functional FBXW7 protein, the immunoprecipitated mTOR is ubiquitinated, whereas SUM149PT cells, which lack FBXW7, show no mTOR ubiquitination. The two right hand lanes show overall ubiquitin levels in the same cell lysates. (see table S1 ). 
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